Deal with Biovitrum Worth $130M Up Front
Amgen Sheds Three Products to Focus on 'Bigger Picture'
By Jennifer Boggs
Tuesday, September 16, 2008
A day before the release of highly anticipated detailed risk-benefit data for osteoporosis drug denosumab, Amgen Inc. said it was divesting three marketed products to Swedish specialty pharma firm Biovitrum AB in exchange for $130 million up front, plus potential sales milestones and royalties down the road. (BioWorld Today)
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.